ABSTRACT
The main objective behind this study was to formulate delayed release colon targeted tablet of Mebendazole by using different polymers. The precompressional parameters of powder blend were studied. The wet granulation method was used for the preparation of tablets. The tablets of all formulation were subjected for different physicochemical evaluation. The drug-excipient interaction study was carried out by using Fourier transforms Infrared spectroscopy [FTIR]. The in vitro evaluation was carried out at different pH ranges [0.1M HCl, 6.8 and 7.4 Phosphate buffer] for the prepared tablets. From the stability, Fourier transform infra-red spectroscopy studies Mebendazole tablet does not show any interaction between drug and polymer. The prepared tablets were complied all the physicochemical test as per official limit. The formulated [M3] batch shows better sustained release 99.89% over a period of 12 hours and the data was fitted into Korsemeyer-Peppas kinetic equation. The result indicates that Mebendazole colon targeted matrix tablet remain stable in the stomach and shows better release into the colon with the help of pH dependent synthetic polymers
ABSTRACT
The present study was undertaken to investigate the effect of hydrophilic, plastic and hydrophobic types of polymers and their content level on the release profile of drug from matrix systems. To improve therapeutic efficacy, systemic absorption and patient compliance a sustained release matrix tablets of Verapamil HCI [VHE] has been developed. VHE tablets were prepared by using various polymers like hydrophilic [HPMC K15M CR], plastic [Kollidon SR], hydrophobic [Eudragit RSPO] and combination of best two resulted polymers using direct compression. A3[2] full factorial design was applied to study the effect of polymers on drug release. For the combination of polymers, selected factors HPMC K15 CR [X[1]] and Eudragit RSPO [X[2]] showed positive influence on drug release at 18 hrs and 20 hrs. The release profile of VHE formulation exhibits Higuchi model with anomalous diffusion release. Accelerated stability trials for 3 months proved reproducibility. A good correlation between the dissolution profiles and bioavailability indicated a linear relationship between in vitro - in vivo data. The current study attained the successful design, development and optimization of controlled release once-a-day formulation of VHE